Navigation Links
GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines

rly two times higher than the monovalent Hib vaccine produced (7.99 mcg/mL vs. 4.39 mcg/mL, respectively).
  • The Hib-MenCY-TT combination vaccine demonstrated an immune response to MenC and MenY in infants that was non-inferior and statistically significantly higher for MenC and non-inferior and comparable for MenY to the immune response induced by ACWY in older children (97.7% of Hib-MenCY-TT had consolidated SBA-MenC response vs. 79.4% of ACWY and 96% of Hib-MenCY-TT had consolidated SBA-MenY response vs. 94.2% of ACWY). The data should be interpreted cautiously given the difference in age of the two treatment groups.
  • Overall grade 3 solicited and unsolicited adverse events (AEs) for the combination Hib-MenCY-TT vaccine were statistically significantly lower than the monovalent Hib vaccine (local AEs were 5.2% in Hib-MenCY-TT vs. 12.9% in Hib and systemic AEs were 8.7% in Hib-MenCY-TT vs. 18.2% in Hib). The most common solicited local AE overall for both the combination Hib-MenCY-TT vaccine and the Hib control groups was pain at the Hib-containing injection site. The most common solicited systemic AE overall for both treatment groups was general irritability.
  • Immunologic interference was not observed when Hib-MenCY-TT was administered with DTaP-Hep B-IPV and pneumococcal 7-valent conjugate vaccine.
  • About Meningococcal Disease

    In the United States each year, there are approximately 2,500 cases of invasive meningococcal disease. Meningitis, an infection caused by Neisseria meningitidis, is a serious and devastating disease with mortality rates of approximately 10% and up to 19% of patients suffering long term effects such as brain damage, amputation, severe skin scarring, kidney damage, mental retardation and deafness. Infants and young children are at the greatest risk for this disease, with approximately 40% of cases occurring in children less than 2
    '"/>




    Page: 1 2 3 4 5

    Related medicine technology :

    1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
    2. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
    3. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
    4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
    5. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
    6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
    7. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
    8. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
    9. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
    10. King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control
    11. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
    Post Your Comments:
    (Date:10/1/2014)... Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") announced ... its Telestroke and Teleneurology services. Dr. Ricardo Garcia-Rivera ... "We are extremely proud that our quality of service ... continue to provide lifesaving support and continuity of care ... throughout the United States ." ...
    (Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
    (Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
    Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
    (Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
    (Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
    (Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
    (Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
    (Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
    Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
    ... too, DENVER, Jan. 30 With the high ... want to heed advice,from two of the country,s leading ... speeches and pep rallies leading up to February 5, ... trail such as cheering,supporters, political pundits, and media analysts, ...
    ... Regional Healthcare System has,selected TransUnion,s Healthcare Revenue Cycle ... streamline administration of its charity,care policy., The ... hospital,system with campuses in Elyria, Amherst, and Avon, ... has served the needs of Lorain County and,greater ...
    ... 30 Sports and,nutritional product manufacturer, Natural Nutrition ... today a forward split of,its common stock. Each ... for every four shares owned as of the ... of record as of February 8, 2008, will ...
    ... stimulation (DBS) surgery, which is used to treat Parkinsons ... for its potential to treat a variety of conditions. ... to treat cluster headaches and aggressiveness in humans, and ... new study found that hypothalamic DBS performed in the ...
    ... Control No Matter Where,You Live, WASHINGTON, Jan. 30 ... the #1 Asthma Capital(TM) -- the most,challenging place to live ... Foundation of America (AAFA)., Since 2004, AAFA has conducted ... in America and to rank,them based on the quality of ...
    ... Jan. 29 John Josef Molenda has joined ... in the Firm,s Intellectual Property,and Appellate and Supreme ... an associate at Frommer Lawrence & Haug,LLP, where ... patent litigation. Dr. Molenda, who has a Ph.D. ...
    Cached Medicine News:Health News:Candidates Risk Harming Voice in Final Week to Super Tuesday 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 3Health News:Natural Nutrition Announces Forward Split of Common Stock 2Health News:Deep brain stimulation may improve memory 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 3
    The clarity and performance of glass with shatterproof safety of plastic....
    Accurate and easy hematocrits in two minutes. Choose glass or easy to read SafeCrit plastic tubes, plain or heparinized. These tubes feature rapid capillary action and have a two-year shelf life. For...
    ... In the Innova™ 4100, the ... X-ray system for angiographic imaging, ... piece, non tiled Digital Detector ... reliably provide high resolution imaging ...
    ... is a bench-top fully automated random ... host of features usually only seen ... has the capacity to perform up ... ISEs, and offers primary tube sampling, ...
    Medicine Products: